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Materials and Methods 
 
Materials. SNC80 ((+)-4- [(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1- piperazinyl)-3-
methoxybenzyl]-N,N- diethylbenzamide), ARM390 (AR-M100390, N,N-diethyl-4-(phenyl-
piperidin-4-ylidenemethyl)-benzamide), Dyngo4a (Dy4) and PitStop2 (PS2) were from Tocris 
(Ellisville, MO). Other reagents, including DADLE ([d-Ala 2-d-Leu 5] enkephalin) and DAMGO 
([d-Ala 2, N-Me-Phe 4, Gly 5-ol] enkephalin), were from Sigma Aldrich (St Louis, MO) unless 
stated otherwise. 
 
Mice. C57BL/6 mice (male, 6-10 weeks) were from Charles River Laboratory (Wilmington, MA, 
USA) and Jackson Laboratory (Bar Harbor, ME, USA). DOPr-eGFP knockin mice (male and 
female, 6-8 weeks) were from B. Kieffer (McGill) and have been described (1). Mice were 
maintained in a light (12 h cycle) and temperature (25°C) controlled environment with free access 
to food and water. Mice were killed by cervical dislocation or anesthetic (isoflurane) overdose and 
bilateral thoracotomy. Animal ethics committees of Queen’s University, Monash University and 
New York University approved all procedures. 
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Mouse colon supernatants. To induce chronic colitis, mice were treated for three cycles with 2% 
DSS in drinking water (each cycle, 5 days DSS and 5 days of normal water). Control mice received 
normal drinking water. Whole colon was cut into segments (~ 1 mm3) and incubated in RPMI 
medium (1 mL per cm colon) containing 10% fetal calf serum, penicillin/streptomycin and 
gentamicin/amphotericin B (95% O2 5% CO2, 24 h, 37°C). Supernatants were stored at -80°C. 
 
Human colon supernatants. Biopsies of mucosa were collected from the descending colon of 
three patients with active chronic ulcerative colitis and three healthy control patients. Disease 
severity was evaluated using the endoscopy component of the Mayo Clinic score for ulcerative 
colitis (Table S1). The protocol was approved by the Queen’s University Human Ethics 
committee. Tissue supernatants were obtained as described (2). 
 
Dissociation of DRG neurons for electrophysiology. DRG neurons (T9-T13) from C57BL/6 
mice were dissociated by incubation with collagenase (1 mg/mL) and dispase (4 mg/mL) for 10 
min at 37 °C, and trituration with a fire-polished Pasteur pipette (3). Cells were plated onto glass 
coverslips coated with laminin (0.017 mg/mL) and poly-D-lysine (2 mg/mL). Neurons were 
cultured in F12 medium containing 10% fetal calf serum, with penicillin and streptomycin and 
maintained at 37 °C in a humidified atmosphere of 95% air and 5% CO2 for 16 h. 
 
Patch clamp recording from DRG neurons. The excitability of small diameter neurons (<30 pF 
capacitance) was assessed by perforated patch-clamp with amphotericin B (240 µg/mL) in current 
clamp mode at room temperature (2-5). Only neurons with resting membrane potentials more 
negative than -40 mV were analyzed. Changes in excitability were quantified by measuring 
rheobase (minimum input current to elicit action potential). Recordings were made using Axopatch 
200B amplifiers, digitized by Digidata 1550B and stored and processed using pClamp 11.03 
software (Molecular Devices). The recording chamber was continuously perfused with external 
solution at 2 mL/min. External solution was (mM): 140 NaCl, 5 KCl, 10 HEPES, 10 D-glucose, 1 
MgCl2, 2 CaCl2; pH to 7.4 with 3 M NaOH. Pipette solution was (mM): 110 K-gluconate, 30 KCl, 
10 HEPES, 1 MgCl2, 2 CaCl2; pH 7.25 with 1 M KOH. To study the effects of endogenous opioids 
released from inflamed colon, neurons were pre-incubated for 60 min with cDSS or HC 
supernatant (50 μL supernatant, 950 μL of F12 medium, filtered) or with cUC or HC supernatants 
(200 μL supernatant, 500 μL of F12 medium, filtered), and were then washed with F12 medium. 
To evaluate the effects of selective OPr agonists, neurons were pre-incubated for 15 min with 
DADLE (10 nM), SNC80 (10 nM), ARM390 (100 nM), DAMGO (10 nM) or vehicle (control) 
and were then washed. Some neurons were also incubated overnight (12-16 h) with DADLE (100 
nM) or ARM390 (300 nM) and were washed. Rheobase was measured at T=0 min or T=30 min 
after washing. To evaluate the participation of specific OPrs, neurons were pre-treated with the 
DOPr antagonist SDM25N (100 nM, 30 min) or the MOPr antagonist CTOP (100 nM, 30 min) 
before supernatant challenge. To investigate the role of endocytosis, neurons were pre-treated with 
Dy4 (30 μM, 30 min) or PS2 (15 μM, 30 min) before supernatant or OPr agonists. To identify the 
signaling pathway responsible for altered excitability, neurons were pre-treated with inhibitors of 
PKC (GF109203X, 1 µM) or MEK1 PD98059 (50 µM) for 30 min before OPr agonists. 
 
Extracellular recording from colonic afferents. The distal colon with attached mesentery 
containing the inferior mesenteric ganglia was excised and mounted in an organ bath continuously 
superfused with gassed (5% CO2, 95% O2) Krebs buffer (mM: NaCl, 118.4; NaHCO3, 24.9; 
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MgSO4, 1.2; KH2PO4, 1.2; glucose, 11.7; CaCl2, 1.9) at 34°C (3). Preparations were opened 
longitudinally along the mesentery border and pinned flat with mucosal side up. The lumbar 
splanchnic nerve was identified in the neurovascular bundle, teased into 5-6 fibers, and 
individually drawn into a glass suction electrode attached to a Neurolog headstage (NL100, 
Digitimer, Welwyn Garden City, UK). Afferent nerve signals were amplified (NL104), filtered 
(NL125 band pass filter), and recorded on a computer with Micro 1401 interface and Spike 2 
software (Version 7, Cambridge Electronic Design, Cambridge, UK). Krebs contained the L-type 
calcium channel blocker nifedipine (3 µM) and the muscarinic acetylcholine receptor antagonist 
atropine (5 µM) to suppress smooth muscle activity, as well as the cyclooxygenase inhibitor 
indomethacin (3 µM) to suppress potential inhibitory actions of endogenous prostaglandins. 
Receptive fields were identified by systematically stroking the mucosal surface and the mesenteric 
attachment with a brush (6, 7). Once identified, receptive fields were tested with 3 distinct 
mechanical stimuli to allow classification: probing (von Frey filament, VFF, 1 g), mucosal stroking 
(0.4 g) and stretch. Vascular afferents that only respond to probing of the gut wall or the mesenteric 
attachment were included. After 30 min equilibration, control probing responses of each unit were 
examined by probing 3 times, each for 3 s (VFF 1 g). OPr agonists (SNC80, ARM390, DAMGO; 
100 nM) were superfused into the organ bath for 15 min. Tissue was washed to remove agonists, 
and afferent responses to VFF probing were re-assessed every 15 min for 60 min. To examine the 
contribution of endocytosis, colonic segments were pre-incubated for 15 min with PS2 (50 µM) 
before challenge with SNC80. PS2 was included throughout the experiment. Single unit activity 
was analyzed offline using the spike sorting function of Spike 2 to discriminate the afferent nerve 
activity of individual units. The afferent response to probing was assessed as average firing 
frequency during a 3-s period using a custom-made script in Spike2. Baseline was assessed as 
average firing frequency during a 120-s period.  
 
cDNAs. Human DOPr (untagged), DOPr with N-terminal extracellular HA epitope (HA-DOPr), 
Gβ1 (untagged), HA-tagged wild-type and K44E dominant negative mutant dynamin I cDNAs 
have been described (8, 9). Gαi1-Rluc8, Gαi2-Rluc8, Gαi3-Rluc8, Gαo-Rluc8, Gαs- Rluc8, Gαq-
Rluc8, and Gγ2-Venus were from C. Gales (Institut des Maladies Métaboliques et 
Cardiovasculaires, Université Toulouse, France) (10). βARR1-YFP and βARR2-YFP were from 
M. Caron (Duke University). KRas-Venus, HRas-Venus, Rab5a-Venus, Rab7a-Venus and 
Rab11a-Venus were from N. A. Lambert (Augusta University) (11). Mini-G proteins coupled to 
Venus were from N. A. Lambert, (Augusta University) (12). Constructs were modified to replace 
Venus with Rluc8. RGFP-CAAX, RGFP-Rab5a and Rluc2-βARR2 were from M. Bouvier 
(Université de Montréal) (13). The plasmid for expression of human DOPr was 
from cdna.org (#OPRD10TN00, Bloomsburg, PA). The coding sequence for DOPr was cloned 
into pcDNA3.1 with a C-terminal Rluc8 tag using NEBuilder HiFi DNA Assembly Cloning from 
New England BioLabs (E5520S, Ipswich, MA). DOPr-Rluc was from G. Pineyro (Universite de 
Montreal, Quebec, Canada) and FRET sensors cytoEKAR GFP/RFP (Addgene plasmid 18680), 
cytoEKAR Cerulean/Venus (Addgene plasmid 18679), nucEKAR GFP/RFP (Addgene plasmid 
18681) and nucEKAR Cerulean/Venus (Addgene plasmid 18681) were from K. Svodoba (Howard 
Hughes Medical Institute, Ashburn, VA, USA) (14), and cytoCKAR (Addgene plasmid 14870) 
and pmCKAR (Addgene plasmid 14862) were from A. Newton (University of California at San 
Diego, CA, USA) (15). βARR1/2 and scrambled have been described (16, 17). 
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Cell culture and transfection. For BRET assays  of G protein activation, HEK293 cells were 
seeded in 10 cm dishes in Dulbecco's Modified Eagle Medium (DMEM) with 10% v/v FBS. Upon 
reaching 50% confluence 24 h post seeding, cells were co-transfected with a total of 5 µg of DOPr: 
Gα-Rluc8: Gβ1: Gγ2-Venus at a ratio of 1.2: 0.3: 1.2: 2.4, respectively. For the βARR1/2 and 
plasma membrane/endosomal trafficking BRET assays, HEK293 cells were co-transfected with 
DOPr-Rluc (1 µg) and βARR1-YFP, KRas-Venus, HRas-Venus, Rab5a-Venus, Rab7a-Venus or 
Rab11a-Venus (4 µg). After 24 h, cells were plated onto poly-D-lysine-coated white 96-well plates 
and cultured for a further 24 h prior to BRET assays. For BRET assays of trafficking of mini-G 
proteins to the plasma membrane or early endosomes, HEK293T cells were transfected using 
JetPEI (Polyplus Transfection, France) with DOPr (0.3 µg) and Rluc8-mGαi/o/s/q (12, 18) (0.3 µg) 
and either Renilla (R) GFP-CAAX (prenylation CAAX box of KRas) (13) (0.4 µg) for cell surface 
activation or RGFP-Rab5a (0.4 µg) for activation in early endosomes. For BRET assays of 
recruitment of βARRs to the plasma membrane or early endosomes, HEK293T cells were 
transfected with JetPEI with DOPr (0.3 µg) and RlucII-βARR2 (13) or Rluc8-βARR1 labeled at 
the C-terminus with the helper peptide Sp1 (19)  (0.1 µg),  and RGFP-CAAX (0.4 µg) for plasma 
membrane recruitment or RGFP-Rab5a (0.4 µg) for early endosome recruitment. For the FRET 
assays of compartmentalized signaling, HEK293 cells were seeded into poly-D-lysine-coated 
black, optically clear 96-well plates. Upon reaching 50-70% confluence 24 h post seeding, 
HEK293 cells were transfected with DOPr (untagged) (55 ng/well) and FRET biosensors (40 
ng/well). An additional 50 ng/well of either the wild-type or K44E dynamin I was transfected for 
the endocytic inhibitory experiments. βARR1/2 knockdown has been described (16, 17). After 24 
h, the cells were subjected to partial serum restriction (0.5% v/v FBS DMEM) overnight prior to 
FRET assays. 
 
Dissociation of DRG neurons for DOPr trafficking and signaling assays. DRG (all levels) from 
DOPr-eGFP mice were digested in Ca2+/Mg2+-free Hank’s Balanced Salt Solution (CMF-HBSS) 
containing collagenase Type IV (2 mg/mL), dispase II (2 mg/mL) and DNAse (0.1 mg/mL) (30 
min, 37°C) (20). DRG were triturated using large, medium and small fire-polished pipettes 30, 15 
and 10 min post-digestion. Neurons were dispersed in 5 mL of DMEM and centrifuged (500 x g, 
5 min). The supernatant was aspirated and the wash was repeated to remove residual enzymes. For 
FRET assays, neurons were nucleofected with 600 ng of the FRET biosensors using a Lonza 4D-
Nucleofector™ system and P3 Primary Cell 4D-Nucleofector™X Kit, according to the 
manufacturer’s instructions. Neurons were resuspended in DMEM containing 10% v/v FBS, 1% 
v/v antibiotic/antimycotic solution (P/S/F) and 1% v/v N1 medium supplement prior to seeding 
into poly-L-lysine- and laminin-coated half area black, optically clear 96-well plate. After 24 h, 
the neurons were subjected to partial serum restriction (DMEM with 0.5% v/v FBS, 1% v/v P/S/F, 
1% v/v N1) overnight prior to FRET assessment. 
 
BRET assays of G protein activation and DOPr and βARR trafficking. HEK293 cells were 
equilibrated in HBSS at 37°C for 30 min. Coelenterazine h (3 µM) was added 15 min prior to 
BRET detection. Cells were challenged with graded concentrations of SNC80, DADLE or 
ARM390. BRET was measured for 3 min before and 15-25 min after agonist stimulation using a 
PHERAstar microplate reader (BMG LabTech, Offenburg, Germany) (16, 17). For the plasma 
membrane/endosomal trafficking assays, BRET was measured for 10-60 min after agonist 
stimulation. The BRET signal was calculated as a ratio of the Venus or YFP emission (530-535 
nm) over the Rluc8 or Rluc emission (430-475 nm). 
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BRET assays of mini-G protein βARR recruitment to the plasma membrane and early 
endosomes. HEK293 cells were washed with Dulbecco’s phosphate-buffered saline, and then 
Tyrode’s buffer was added. After the addition of Prolume Purple Coelenterazine (2.5 µM; 
NanoLight Technology), the cells were incubated for 5 min at 37°C. BRET was recorded for 22.5 
min in a Synergy Neo2 Microplate reader (BioTek) (acceptor filter: 515 ± 30 nm; donor filter: 410 
± 80 nm). Cells were challenged with SNC80, DASDLE or ARM390 (100 nM) after 2.5 min.  In 
some experiments, cells were pretreated with pertussis toxin (X µM, X min). D-BRET represents 
the BRET signal in the presence of agonist subtracted by the BRET signal in the presence of 
vehicle.  
 
FRET assays of compartmentalized signaling. HEK293 cells and DRG neurons were 
equilibrated in HBSS at 37°C. Images were captured at 1 min intervals using a GE Healthcare 
INCell 2000 Analyzer with a Nikon Plan Fluor ELWD 40x (NA 0.6) objective and FRET module 
(Little Chalfont, UK) as described (17, 20). For the GFP/RFP ERK biosensors, cells were 
sequentially excited using a light source with a FITC filter (490/20) and emission was measured 
using dsRed (605/52) and FITC (525/36) filters in addition to a polychroic filter (Quad 4) 
optimized for the FITC/dsRed filter pair. For the Cerulean/Venus ERK biosensors and the PKC 
biosensors, cells were sequentially excited using a light source with a CFP filter (430/24) and 
emission was measured using YFP (535/30) and CFP (470/24) filters in addition to a polychroic 
filter (Quad3) optimized for the CFP/YFP filter pair. GFP/RFP ERK biosensors were used in 
HEK293 cells whereas the Cerulean/Venus ERK biosensors were used for the GFP-dynamin and 
DRG experiments to avoid GFP interference. Cells were challenged with SNC80, DASDLE or 
ARM390 (100 nM). Baseline images were taken for 4 min prior to stimulation. Upon addition of 
ligands, images of the stimulated cells were taken for 20 min. Cells were then stimulated with 
positive control compounds (200 nM phorbol 12,13 dibutyrate (PDBu) for ERK biosensors, or 200 
nM PDBu with phosphatase inhibitor cocktail for PKC biosensors) for 10 min to generate maximal 
responses. HEK293 cells and DRG neurons were pre-treated with the dynamin inhibitor Dy4 (50 
µM) (Abcam, Cambridge, MA), the clathrin inhibitor PS2 or inactive PS2 (30 µM) (Abcam, 
Cambridge, MA) or vehicle (1% DMSO) for 30 min and inclusion throughout. FRET images were 
automatically collated and aligned in the order of baseline, stimulated and positively stimulated 
prior to manual selection with the aid of scripts as described. The baseline subtracted ratio relative 
to positive control (F/Fmax) for each cell was then graphed if the selection criteria of having greater 
than 5% change in emission ratio relative to baseline (F/F0) post positive control stimulation was 
met.  
 
Immunofluorescence. After FRET imaging, DRG were fixed with 4% paraformaldehyde (PFA) 
(20 min at 4°C). Neurons were blocked with 5% normal horse serum (NHS) and 0.1% saponin in 
PBS, and incubated with rabbit anti-GFP (#A11122, ThermoFisher Scientific; 1:1000) and mouse 
anti-NeuN (clone A60, Merck Millipore, Bedford, MA; 1:200) (overnight, 4°C). Neurons were 
washed with PBS and incubated with donkey anti-mouse Alexa Fluor 647 (1:500) and donkey 
anti-rabbit Alexa Fluor 488 (1:1000) (ThermoFisher Scientific) (2 h, RT). Images were captured 
using the INCell 2000 Analyzer with Cy5 (645/30) and FITC (490/20) as the excitation filters and 
Cy5 (705/72) and FITC (525/36) as the emission filters in addition to a polychroic filter (Quad 
4). FRET was only analyzed in neurons expressing DOPr-eGFP. 
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DOPr-eGFP trafficking in DRG neurons. DRG (all levels) were collected from DOPr-eGFP 
mice. Neurons were dispersed and plated on poly-l-lysine/laminin-coated glass coverslips. After 
48 h, neurons were exposed to vehicle, DADLE (1 µM), DADLE-LipoMSN-Alexa647 (1 µM 
DADLE, 10 µg/mL LipoMSN) or LipoMSN-Alexa647 (10 µg/mL LipoMSN, control) (30 or 60 
min, 37°C in serum-free DMEM). In some experiments, neurons were preincubated with Dy4 (30 
µM) or PS2 (15 µM) (30 min preincubation, inclusion throughout). Neurons were fixed in 4% 
PFA for 20 min on ice, and then blocked 5% NHS, 0.1% Triton X-100 in PBS containing 0.1% 
sodium azide (1 h, RT). Neurons were incubated with rabbit anti-GFP (#A11122, ThermoFisher 
Scientific; 1:1000) and mouse anti-HuC/HuD (# A-21271, 16A11, ThermoFisher Scientific; 
1:1000) (overnight, 4°C). Neurons were washed in PBS and incubated with donkey anti-rabbit 
A488 and donkey anti-mouse A568 (ThermoFisher Scientific; 1:500) (1 h, RT in PBS). Neurons 
were imaged using a Leica TCS SP8 confocal microscope (40x objective, 1024x1024 and 
2048x2048 resolution, 16-bit depth). 
 
MSN Synthesis. MSNs were prepared as described (21). 
Sodium diselenide. Sodium diselenide was prepared by reaction of selenium powder and sodium 
borohydride in water as described. Sodium borohydride 0.15 g (4.0 mmol) was dissolved in 2 mL of 
deionized water and mixed with selenium powder 0.32 g (2.0 mmol). The selenium was dissolved, 
generating hydrogen gas and resulting in a colorless solution within ~5 min. The flask was sealed and 
the solution was heated to 70°C for 20 min, resulting in a dark red solution. A solution of benzyl bromide 
0.68 g (4.0 mmol) in 5 mL refined tetrahydrofuran (THF) was injected into the flask under argon gas. 
The reaction proceeded at 50°C for 12 h, the product was extracted with CH2Cl2 and dried under 
anhydrous MgSO4. Evaporation and vacuum drying formed dibenzyldiselinide as a yellow solid. 
Bibenzyldiselinide was then dissolved in 5 mL THF and added into a 2 mL solution of 0.15 g sodium 
borohydride. After stirring for 10 min, the solution became colorless and 1.0 g (4 mmol) 11-
bromoundecanol in 5 mL THF solution was added. The flask was incubated at 50°C overnight, and the 
reaction mixture was then extracted with CH2Cl2, desiccated by MgSO4 and concentrated. The crude 
product was purified using column chromatography by 2 elution steps with CH2Cl2 and then diethyl 
ether. A white powder, 11-(benzylselanyl)undecan-1-ol, was obtained (yield 70%). 
Bis[3-(triethoxysilyl)propyl]diselenide. Bis[3-(triethoxysilyl)propyl]diselenide (BTESePD) was 
prepared by the reaction of γ-chloropropyl trimethoxysilane with freshly prepared sodium 
diselenide as described. γ-chloropropyl trimethoxysilane (10 g) was added into 30 mL of sodium 
diselenide stock solution and stirred at room temperature overnight. Ice water was used to quench 
the reaction. The mixture was extracted with dichloromethane and the organic layer was dried with 
anhydrous sodium sulfate. The crude product was purified by silica-gel column chromatography 
(PE:DCM, 10:1-1:1) to obtain the product, appearing as a dark yellow liquid (1.8 g, yield 18%). 
Biodegradable MSNs. Biodegradable MSNs were synthesized through a modified sol-gel method 
using cetyltrimethylammonium tosylate (CTAT) as a template, TEOS and bis-silylated precursors 
with diselenide-bridged groups as co-silica sources as described. To prepare diselenide-bridged 
MSNs, 0.6 g CTAT, 0.15 g triethanolamine (TEAH3) and 40 mL deionized water were stirred at 
80°C for 30 min. A solution of 4.0 g TEOS and 1.0 g bis[3-(triethoxysilyl)propyl]diselenide 
(BTESePD) was added dropwise to the surfactant solution and mixed at 80°C for 4 h. The products 
were collected by centrifugation, washed three times with ethanol, and then refluxed in an ethanol 




DOPr-targeted liposome synthesis 
Cationic liposome assembly. Lipid was formulated into liposomes for all delivery applications as 
described (22). 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP) was mixed with 
cholesterol, dioleoylphosphatidylethanolamine (DOPE), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2000-malemide) 
(Avanti Polar Lipids) at a molar ratio of 65:30:3.75:12.5. Briefly, DOTAP, cholesterol, DOPE and 
half of the DSPE-PEG were mixed in a chloroform solution. The organic solvent was evaporated 
under vacuum and further dried over night to form a thin layer film. The lipid film was hydrated 
using a mixed solution of ethanol/sodium acetate buffer (200 mM, pH 5.2, vol:vol, 9:1). The 
solution was added dropwise to an aqueous solution containing the rest of the DSPE-PEG, and the 
resulting solution was incubated at 37°C for 30 min before dialysis against water in 3500 molecular 
weight cut-off cassettes. 
Liposome conjugation to DADLE. DADLE was covalently tethered to the maleimide end of the 
DSPE-PEG-2000-maleimide inserted into the liposome by a thioether bond (23). To ensure correct 
orientation of the DADLE, a C-terminal cysteine residue was added to the DADLE peptide before 
reacting the DADLE with the formulated liposome. DADLE-cysteine and liposomes were mixed 
in a 1:1 molar ratio in 20 mM MES, 20 mM HEPES, pH 6.5 buffer under inert N2 conditions (4°C, 
overnight, dark, gentle stirring). The reaction was dialyzed against water in 3500 molecular weight 
cut-off cassettes.  
 
Cargo loading and liposome coating 
MSN core-loading. DADLE, Alexa647-DADLE or Alexa647 (10 mM) was added to aqueous 
MSN (1 mg/mL) in 1:10 ratio (wt:wt). The solution was shaken at 500 rpm at 4°C for 30 min. To 
remove excess DADLE, the solution was centrifuged (10,000 g, 4°C, 10 min) and supernatant was 
discarded. The pellets of MSN-DADLE, MSN-Alexa647-DADLE or MSN-Alexa647 were 
resuspended by pipetting and sonication (2 min).  
Liposome coating. Liposomes and MSNs were combined in aqueous solution in a 1:1 ratio (wt:wt). 
The solution was shaken at 500 rpm at 4°C for 30 min. To remove excess liposome, the solution 
was centrifuged (10,000 g, 4°C, 10 min) and supernatant was discarded. The pellet of LipoMSN 
was resuspended by pipetting and sonication (2 min). 
 
LipoMSN-SDM25N synthesis 
Cationic liposome assembly. Liposomes were formulated as described above with DOTAP, 
cholesterol, DOPE, and DSPE-PEG2000 at a molar ratio of 65: 30: 3.5: 17.5.  
MSN core-loading. MSNs (1 mg/mL) were loaded with SDM25N (10 mM) in 1:10 ratio (wt:wt) 
as described above.  
Liposome coating. MSN-SDM25N were coated with liposomes as described above.  
 
Physicochemical characterization of LipoMSNs 
Transmission electron microscopy. The morphology of the nanoparticles was characterized using 
a JEM-2100F transmission electron microscope (TEM, JEOL, Ltd., Japan). 
Size and charge. The hydrodynamic diameter and zeta potential of the nanoparticles in water or 
PBS were determined using a Nano-ZS 90 Nanosizer (Malvern Instruments Ltd., Worcestershire, 
UK).  
Drug-loading efficiency. DADLE and SDM25N loading of MSNs was measured by absorbance 
using a Fluostar Optima plate reader (BMG Labtech, Ortenberg, Germany). Supernatant was 
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collected after loading the MSN core with DADLE or SDM25N and the concentration was 
measured at 280 nm or 290 nm with a standard curve of DADLE or SDM25N, respectively. The 
supernatant concentration was used to calculate the unloaded fraction of peptide, yielding the 
remaining as the loaded fraction. 
pH- and glutathione-sensitive cargo release. To determine the pH or redox-sensitive cargo release 
from LipoMSN, Alexa Fluor 647-tagged DADLE (DADLE-647) was loaded into the MSN and 
the fraction loaded was calculated by supernatant measurement. For pH-sensitive release, 
DADLE-647-MSNs were incubated in PBS (pH 7.2) or sodium acetate buffer (pH 5.2), or with 
and without 10 mM glutathione. Supernatant was collected by centrifugation (10,000 g, 12 min) 
at 30 min, 1 h, 2 h, 4 h and 24 h time points. DADLE-647 released into the supernatant was 
determined by measurement of fluorescence using a Fluostar Optima plate reader (BMG Labtech, 
Ortenberg, Germany), and total DADLE-647 released in each time frame was calculated. Standard 
curves of DADLE-647 were generated in both buffers. For redox-sensitive release, DADLE-647-
MSNs were incubated in an aqueous solution with or without 10 mM glutathione. Release of 
DADLE-647 was measured as described, using standard curves in aqueous solution with or 
without glutathione. 
 
Cellular targeting of LipoMSNs. The MSN core of DADLE-LipoMSNs and LipoMSNs was 
loaded with Alexa Fluor 647. HEK293T cells were transfected using polyethylenimine with 5 µg 
cDNA encoding human HA-DOPr; untransfected cells were used as controls. Cells were plated 24 
h after transfection. For flow cytometry experiments, cells were seeded at 100,000 cells per well 
in a 24-well plate and cultured overnight. Cells were incubated with DADLE-LipoMSN-Alexa647 
or LipoMSN-Alexa647 (40 µg/mL) in Opti-MEM for 0-4 h. Uptake of nanoparticles was 
quantified by flow cytometry (LSRFortessa Cell Analyzer, BD Biosciences, Mississauga, 
Canada). In some experiments, cells were preincubated with Dy4, PS2 or inactive analogs (10 
µg/mL) for 30 min before addition of nanoparticles. For imaging studies, cells were seeded at 
30,000 cells onto poly-D-lysine-coated glass coverslips and were infected with Rab5a-GFP 
(CellLight Early Endosome-GFP, ThermoFisher Scientific; 3 µL/10,000 cells). After 24 h, cells 
were pre-incubated with rat anti-HA (Roche clone 3F10; 1:500) in HBSS (30 min, 4°C). Cells 
were washed and then incubated in HBSS with DADLE-LipoMSN-Alexa647 (20 µM DADLE, 
200 µg/mL LipoMSN, 4°C, 0-30 min) or LipoMSN-Alexa647 (200 µg/mL LipoMSN, 4°C, 0-120 
min). Cells were fixed in 4% PFA (20 min, 4°C), and blocked in PBS containing 3% NHS, 0.3 % 
saponin and 0.1% sodium azide (1 h, RT). Cells were incubated with goat anti-rat Alexa Fluor 568 
(ThermoFisher Scientific; 1:1000) (1h, RT) and then with DAPI (10 µg/µL, 5 mins, RT). Cells 
were imaged by confocal microscopy as described above. 
 
Live cell imaging of LipoMSN uptake. HEK293 cells expressing HA-DOPr were seeded on 
poly-D-lysine coated 35 mm glass bottom dishes (30,000 cells/dish, MatTek) and infected with 
the Rab5a-GFP. After 48 h, cells were washed and equilibrated in HBSS (30 min, RT). Images 
were collected every 15 s for 40 min on a Leica SP8 confocal microscope with a 63x (NA 1.4) 
objective. After recording baseline for 1 min, cells were challenged with LipoMSN-Alexa647 (200 
µg/mL LipoMSN, control) or DADLE-LipoMSN-Alexa647 (20 µM DADLE, 200 µg/mL 
LipoMSN). Image sequences were processed in ImageJ and videos were rendered in Adobe After 
Effects. 
 
DADLE-LipoMSN-DADLE and DOPr signaling 
 9 
cAMP assays. HEK293 cells were co-transfected with 1 µg DOPr and 4 µg CAMYEL cDNA. 
Cells were plated and BRET was measured after 48 h, as described above. Cells were challenged 
with forskolin (10 µM, 5 min) to induce cAMP production and were then exposed to DOPr 
agonists. 
βARR1 recruitment. HEK293 cells were co-transfected with 1 µg DOPr-Rluc8, 1 µg GRK2 and 3 
µg βARR1-YFP cDNA. Cells were plated and BRET was measured after 48 h, as described above.  
Nuclear ERK assays. HEK293 cells were co-transfected with 1 µg DOPr and 4 µg NucEKAR 
nuclear ERK FRET biosensor. Cells were plated and FRET was measured after 48 h, as described 
above. Cells were challenged with PDBu (1 µM) or DOPr agonists. FRET ratios were normalized 
to baseline and to the vehicle control. 
Drug treatments. Cells were challenged with DADLE (100 nM), DADLE-LipoMSN (20 µM 
DADLE, 200 µg/mL LipoMSN), DADLE-LipoMSN-DADLE (20 µM DADLE, 160 µg/mL 
LipoMSN), LipoMSN (200 µg/mL, control), or vehicle.  
 
DADLE-LipoMSN-DADLE and electrophysiology 
Nociceptor excitability. Rheobase was measured at 0, 90, 120 or 180 min after exposure to 
nanoparticles and washing, as described above. To evaluate the contribution of endocytosis, 
neurons were pre-incubated with PS2 (15 µM, 30 min and inclusion throughout). 
Colonic afferent activity. Colonic afferent responses (1 g VFF) were assessed at 0, 60 and 120 min 
after exposure to nanoparticles and washing, as described above. To evaluate the contribution of 
endocytosis, colon preparations were preincubated with PS2 (50 µM, 15 min and inclusion 
throughout). 
Drug treatments. DRG neurons were preincubated with DADLE (100 nM), DADLE-LipoMSN 
(100 nM DADLE, 1 µg/mL LipoMSN), DADLE-LipoMSN-DADLE (100 nM DADLE, 0.8 
µg/mL LipoMSN), LipoMSN (1 µg/mL, control) or vehicle (control) for 30 min and then washed 
before measurement of rheobase. Colon preparations were preincubated with DADLE-LipoMSN-
DADLE (100 nM DADLE, 0.8 µg/mL LipoMSN) for 30 min and then washed before recording 
colonic afferent activity. 
 
LipoMSN-SDM25N and electrophysiology 
Nociceptor excitability. Rheobase was measured at 0 or 30 min after exposure to nanoparticles and 
washing, as described above. 
Drug treatments. DRG neurons were preincubated with LipoMSN-SDM25N (100 nM SDM25N, 
100 µg/ml LipoMSN) or LipoMSN (100 µg/ml, control) for 120 min and then washed before 
measurement of rheobase 0 or 30 min after washing. 
 
DADLE-LipoMSN-DADLE and inflammatory pain. The investigator was blinded to the 
treatments. Mice were randomly assigned to treatments (www.randomization.org). Nociception 
was assessed from 8 am to 1 pm. Mice were acclimatized to the investigator, room and restraint 
apparatus for 2 h/day on 2 successive days before experiments. Complete Freund’s Adjuvant 
(CFA, 0.5 mg/mL) was administered by intraplantar injection (10 µL) into the left hindpaw of 
sedated mice (4% isoflurane). Drugs were administered by intrathecal (i.t.) injection 48 h after 
CFA, which is the peak of inflammation in this model of inflammatory pain. DADLE (100 nM), 
DADLE-LipoMSN-DADLE (100 nM DADLE, 0.8 µg/mL LipoMSN), LipoMSN (1 µg/mL 
LipoMSN, control) or vehicle (control) was injected intrathecally (5 µL) to sedated mice (4% 
isoflurane). To assess mechanical hyperalgesia, mice were placed in individual plexiglass boxes 
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on a mesh stand. Paw withdrawal in response to stimulation of the plantar surface of the hind paw 
with graded VFF was determined using the “up-and-down” paradigm (17, 24). VFF withdrawal 
thresholds were measured in triplicate to establish a baseline for each mouse on 2 consecutive days 
before the experiments. Withdrawal thresholds were measured at 1 h intervals for 7 h after i.t. drug 
administration. Results were normalized to the baseline withdrawal thresholds obtained during the 
2 consecutive days of baseline and are expressed as a percentage of baseline.  
 
Statistics. Studies in vitro and using cell lines were replicated in at least three independent 
experiments (N), with triplicate observations in each experiment. For electrophysiological and 
behavioral studies, the number of replicates (N) was determined from published studies using 
similar approaches. All results were included and outliers were not excluded. Results were 
analyzed and graphs prepared using Prism 8 (GraphPad, San Diego, CA). Results are expressed 
as mean±SEM. Statistical significance was assessed using t-tests or 1-way or 2-way ANOVA with 








Fig. S1. DOPr signaling and trafficking in HEK293 cells. FRET and BRET biosensors were 
coexpressed with DOPr in HEK293 cells. A-D. Time course of effects of SNC80, DADLE and 
ARM390 (all 100 nM, arrow) on BRET between Gαi1-Rluc8 (A), Gαo-Rluc8 (B), Gαs-Rluc8 (C) 
or Gαq-Rluc8 (D) and Gγ-Venus. E-G. Effects of graded concentrations of SNC80 (E), DADLE 
(F) and ARM390 (G) on BRET between Gαi1,2,3-Rluc8 isoforms or Gαo-Rluc8 and Gγ-Venus. 
BRET was measured at 5 min after agonist addition. Boxes show pEC50 values. H, I. Time course 
of effects of SNC80, DADLE and ARM390 (all 100 nM, arrow) on BRET between DOPr-Rluc 
and βARR1-YFP (H) or βARR1-YFP (I). J, K. Effects of graded concentrations of SNC80, 
DADLE and ARM390 on BRET between DOPr-Rluc and βARR1-YFP (J) or βARR2-YFP (K). 
BRET was measured at 10 min after agonist addition. Boxes show pEC50 values. L-K. Effects of 
SNC80, DADLE and ARM390 (all 100 nM, arrow) on BRET between DOPr-Rluc and the plasma 
membrane proteins HRas-Venus (L, M) and KRas-Venus (M), and the endosomal proteins Rab5a-
Venus (N, early endosomes), Rab7a-Venus (O, late endosomes), and Rab11a-Venus (P, recycling 
endosomes). L. Time course. M-P. Area under curve (AUC) of 60 min time course. Data points 
show results of independent experiments. N=3 (A-G) or 3-8 (H-K) independent experiments 




Fig. S2. Activation of G proteins and βARRs at the plasma membrane and in early 
endosomes of HEK293 cells. A. Localization of GFP-Rab5a BRET sensor in endosomes (arrows). 
B-K. Bystander BRET for Rluc8-Gasi/o/s/sq proteins or Rluc2-βARR1/2 and plasma membrane 
RGFP-CAAX. B, D, F, G, H, J, L show time courses. C, E, I, K show area under curve over 15 
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min (AUC). L-U. Bystander BRET for Rluc8-Gasi/o/s/sq proteins or Rluc2-βARR1/2 and early 
endosomal RGFP-Rab5a. L, N, P, Q, R, T show time courses. M, O, S, U show area under curve 
over 15 min. Effects of pertussis toxin (PTX) are show in H-K and R-U. N=5 (mean±SEM). 







Fig. S3. Endosomal DOPr-mediated PKC and ERK signaling in subcellular compartments 
of HEK293 cells. FRET biosensors for plasma membrane and cytosolic PKC (pmCKAR, 
cytoCKAR) or cytosolic and nuclear ERK (cytoEKAR, nucEKAR) were coexpressed with DOPr 
in HEK293 cells. Cells were pretreated with vehicle, PS2 inactive or PS2. A. Plasma membrane 
PKC activity. B. Cytosolic PKC activity. C. Cytosolic ERK activity. D. Nuclear ERK activity. 
Integrated responses over 20 min (area under the curve, AUC). Data points show results of 
independent experiments. N=3 (A, B), N=4 (C, D) independent experiments (mean±SEM). 





Fig. S4. Uptake and signaling of DADLE nanoparticles in HEK293 cells. A. Uptake of 
DADLE-LipoMSN-DADLE-Alexa647 into HEK-HA-DOPr cells after 30 min. Representative 
images, N=4 experiments. B, C. Effects of DADLE (100 nM), DADLE-LipoMSN (20 µM) and 
DADLE-LipoMSN-DADLE (20 µM) on forskolin (FSK, 10 µM)-stimulated cAMP formation in 
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HEK-DOPr cells (B, AUC, area under curve) and HEK293 control cells (C). Effects of DADLE 
(100 nM), DADLE-LipoMSN (20 µM) and DADLE-LipoMSN-DADLE (20 µM) on bARR1 
recruitment (C) and activation of nuclear ERK (D) in HEK-DOPr cells. Data points show results 
of independent experiments. N=5 experiments (B), N=5 experiments (C-E) (mean±SEM). 





Fig. S5. Agonist-evoked endocytosis of DOPr-eGFP in nociceptors and assessment of 
nociception in mice. A. Localization of DOPr-eGFP in DRG neurons from DOPr-eGFP knockin 
mice after incubation with DADLE (1 µM) or vehicle for 60 min. Representative images of N=4 
experiments. B. Contralateral paw withdrawal responses in mice. DADLE, DADLE-LipoMSN-
DADLE (both 100 nM DADLE), LipoMSN or vehicle (Veh) was injected intrathecally at 48 h 





Fig. S6. Agonist stimulated trafficking of DOPr mediates compartmentalized signaling and 
antinociception. 1. Opioids from the inflamed colon, internalizing agonists (DADLE, SNC80), 
and DADLE-LipoMSN-DADLE activate plasma membrane DOPr, which couples to activation of 
Gαi/o and recruits βARRs. 2. DOPr undergoes clathrin- and dynamin-mediated endocytosis. Within 
endosomes, DOPr continues to signal. 3. When activated by opioids from the inflamed colon, 
internalizing agonists (DADLE, SNC80), and DADLE-LipoMSN-DADLE, endosomal DOPr 
generates sustained signals. 4. Endosomal DOPr activates plasma membrane and cytosolic PKC in 











Age (y) Sex Treatment 
Ulcerative 
colitis 
> 3 months Mayo 1 49 M 5-ASA 
Ulcerative 
proctitis 
> 3 months Mayo 2 59 F 5-ASA 
Ulcerative 
colitis 
> 3 months Mayo 1-2 62 M 5-ASA 
 
MAYO score 0-3. 5-ASA, 5-aminosalisylic acid.  
 
Table S2. Statistical tests 
 
Experiment Statistical tests 
Excitability of DRG nociceptors 2-way ANOVA, Tukey’s test 
Excitability of colonic nociceptors 2-way ANOVA, Tukey’s test, Sidak’s test 
BRET assays 1- or 2-way ANOVA, Tukey’s test 
FRET assays 1- or 2-way ANOVA, Tukey’s test 
Nanoparticle uptake T-test, Holm-Sidak correction 
1-way ANOVA, Tukey’s test 
Nociceptive behavior 2-way ANOVA, Tukey’s test 
 
Movie S1. Uptake of DADLE-LipoMSN-Alexa647 into HEK-DOPr cells. HEK-HA-DOPr 
cells expressing Rab5a-GFP were incubated with DADLE-LipoMSN-Alexa647 (20 µM DADLE). 
Live cells were imaged by confocal microscopy. 
 
Movie S2. Lack of uptake of LipoMSN-Alexa647 into HEK-DOPr cells. HEK-HA-DOPr cells 
expressing Rab5a-GFP were incubated with LipoMSN-Alexa647 (control). Live cells were 
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